Safety and Efficacy of Coformulated Pembrolizumab/Quavonlimab in Combination With Lenvatinib in Advanced Hepatocellular Carcinoma
The purpose of this study is to evaluate the safety and efficacy of fixed dose coformulated pembrolizumab/quavonlimab (MK-1308A) plus lenvatinib in a first line (1L) hepatocellular carcinoma (HCC) setting. No hypothesis